Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising...

Area of Science:

• Gynecology
• Oncology
• Pediatric Oncology

Background:

• Malignant ovarian germ cell tumours (MOGCTs) are rare, affecting young females, unlike common epithelial ovarian cancers.
• Current treatment relies on fertility-sparing surgery and platinum-based chemotherapy, adapted from testicular germ cell tumour protocols.
• Platinum-resistant MOGCTs have a poorer prognosis compared to their male counterparts, highlighting a treatment gap.

Purpose of the Study:

• To review current systemic anti-cancer treatments for MOGCTs.
• To explore promising novel therapeutic approaches for MOGCTs.
• To emphasize the need for dedicated research in female germ cell tumours.

Main Methods:

• Literature review of current systemic anti-cancer treatment options for MOGCTs.
• Analysis of existing evidence and clinical guidelines.
• Discussion of promising future therapeutic strategies.

Main Results:

• Standard care includes fertility-sparing surgery and platinum-based chemotherapy, yielding high cure rates.
• Chemotherapy regimens are often extrapolated from testicular germ cell tumours due to limited MOGCT-specific data.
• Platinum-resistant/refractory MOGCTs present a significant challenge with a worse prognosis.

Conclusions:

• There is a critical need for high-quality studies specifically for MOGCTs.
• Future research should focus on female-only trials or include MOGCT patients in broader germ cell tumour studies.
• Developing novel treatment strategies is essential to improve outcomes for platinum-resistant MOGCTs.